Phase II Pilot Study of Cyclophosphamide and Rabbit Anti-Thymocyte Globulin as Salvage Therapy in Patients With Diffuse Systemic Sclerosis
Completed
Fred Hutchinson Cancer Research Center
Phase 2
2000-06-01
OBJECTIVES: I. Determine the toxicity of cyclophosphamide and rabbit anti-thymocyte globulin
in patients with diffuse systemic sclerosis.
II. Determine the efficacy of this regimen in terms of controlling disease in these patients.
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer
Completed
National Cancer Institute (NCI)
Phase 2
2002-12-01
RATIONALE: Giving low doses of chemotherapy, such as fludarabine and busulfan, before a donor
bone marrow or peripheral blood stem cell transplant helps stop the growth of cancer cells.
It also stops the patient's immune system from rejecting the donor's stem cells. The donated
stem cells may replace the patient's immune system and help destroy any remaining cancer
cells (graft-versus-tumor effect). Giving an infusion of the donor's T cells (donor
lymphocyte infusion) after the transplant may help increase this effect. Sometimes the
transplanted cells from a donor can also make an immune response against the body's normal
cells. Giving immunosuppressive therapy after the transplant may stop this from happening.
PURPOSE: This phase II trial is studying how well donor bone marrow or peripheral stem cell
transplant works in treating patients with relapsed hematologic cancer after treatment with
chemotherapy and autologous stem cell transplant.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
